Samsung Bioepis' Marketing Authorization Application for SB3 Trastuzuma
SB3, a biosimilar candidate referencing Herceptin (trastuzumab), is Samsung ...
2016-10-11
文传商讯
Samsung Bioepis' SB4 (BRENZYS) Becomes First Etanercept Biosimilar to R
Canadian approval of BRENZYS, a biosimilar referencing Enbrel (etanercept), ...
2016-09-13
文传商讯
Samsung Bioepis' Marketing Authorization Application for SB5 Adalimumab
If approved, SB5, a biosimilar candidate referencing Humira® (adalimumab...
2016-07-19
文传商讯
Samsung Bioepis Announces New Data on Three Anti-TNF-伪 Biosimilar Mole
Switching data on Benepali® (etanercept), Flixabi® (infliximab) and ...
2016-06-15
文传商讯
Samsung Bioepis Becomes First to Obtain European Commission Approval fo
Samsung Bioepis solidifies industry leadership in biosimilars by becoming th...
2016-05-30
文传商讯
Samsung Bioepis' Biologics License Application for SB2 Infliximab Biosi
INCHEON, Korea -- (BUSINESS WIRE) --Samsung Bioepis Co., Ltd. today announce...
2016-05-24
文传商讯
Samsung Bioepis' Flixabi® Infliximab Biosimilar Recommended for App
Samsung Bioepis’ Flixabi® receives positive opinion from the Commi...
2016-04-06
文传商讯
Samsung Bioepis Enters the European Biopharmaceutical Market with Benep
In just under four years, Samsung Bioepis develops, tests and receives regul...
2016-01-18
文传商讯
